Total submissions: 22
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
International Society for Gastrointestinal Hereditary Tumours |
RCV000030367 | SCV000108339 | no known pathogenicity | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | MAF >1% |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000030367 | SCV000053034 | benign | Lynch syndrome | 2011-08-18 | criteria provided, single submitter | clinical testing | Converted during submission to Benign. |
Gene |
RCV001711093 | SCV000171038 | benign | not provided | 2018-12-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000162407 | SCV000212741 | benign | Hereditary cancer-predisposing syndrome | 2014-09-15 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Eurofins Ntd Llc |
RCV000174490 | SCV000225799 | benign | not specified | 2018-03-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000755369 | SCV000252716 | benign | Hereditary nonpolyposis colorectal neoplasms | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000409560 | SCV000488722 | benign | Lynch syndrome 4 | 2016-06-01 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001711093 | SCV000604893 | benign | not provided | 2023-10-23 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000174490 | SCV000806202 | benign | not specified | 2016-11-10 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000409560 | SCV001322358 | uncertain significance | Lynch syndrome 4 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Genetic Services Laboratory, |
RCV000174490 | SCV002069905 | benign | not specified | 2021-09-29 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000162407 | SCV002530278 | benign | Hereditary cancer-predisposing syndrome | 2020-10-13 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000174490 | SCV002760372 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001711093 | SCV002821800 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | PMS2: BP4, BP7 |
Myriad Genetics, |
RCV000409560 | SCV004019873 | benign | Lynch syndrome 4 | 2023-04-05 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |
Color Diagnostics, |
RCV000162407 | SCV004359028 | benign | Hereditary cancer-predisposing syndrome | 2021-07-26 | criteria provided, single submitter | clinical testing | |
Pathway Genomics | RCV000144648 | SCV000189975 | benign | Lynch syndrome 1 | 2014-07-24 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001353992 | SCV000592949 | benign | Endometrial carcinoma | no assertion criteria provided | clinical testing | PMS2, EXON13, c.2253T>C, p.Phe751Phe, Benign (ACMG 5) The PMS2 c.2007-7C>T variant was identified in 16 of 1346 proband chromosomes (frequency: 0.012) from individuals or families with Lynch Syndrome and HNPCC (14756672_Thompson_2004, 20698049_sheng_2010). However, control chromosomes were not evaluated in these studies, thus the prevalence of this variant in the general population could not be determined. The variant was also identified in dbSNP (ID: rs1805325) “With benign allele”, and in the “InSiGHT Colon Cancer Database”. The p.Phe751Phe variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. Computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein. In summary, based on the above information, this variant meets our laboratory's criteria to be classified as benign. | |
Mayo Clinic Laboratories, |
RCV000174490 | SCV000691960 | benign | not specified | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV000174490 | SCV001799750 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000174490 | SCV001807782 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000174490 | SCV001964212 | benign | not specified | no assertion criteria provided | clinical testing |